In Brief: EXPLANATIONS & EXCULPATIONS
Executive Summary
EXPLANATIONS & EXCULPATIONS: Eisai E2020: NDA for Alzheimer's treatment will be filed by Eisai America, Inc. in 1996. "If approved, Eisai Inc. and Pfizer will co-promote E2020 using a joint Pfizer-Eisai detail force, managed and trained by Pfizer, throughout the U.S.," Eisai says. "All clinical development and regulatory activities for E2020 have been conceived, directed and conducted through Eisai's U.S. subsidiary, Eisai America, Inc." The Oct. 30 issue of "The Pink Sheet" (p. 11) incorrectly described the collaboration between Pfizer and Eisai...